🇺🇸 Pegylated Interferon alpha-2a in United States
20 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 20
Most-reported reactions
- Anorexia — 2 reports (10%)
- Ascites — 2 reports (10%)
- Back Pain — 2 reports (10%)
- Diarrhoea — 2 reports (10%)
- Drug Intolerance — 2 reports (10%)
- Dry Mouth — 2 reports (10%)
- Hepatic Failure — 2 reports (10%)
- Jaundice — 2 reports (10%)
- Oedema — 2 reports (10%)
- Renal Failure — 2 reports (10%)
Frequently asked questions
Is Pegylated Interferon alpha-2a approved in United States?
Pegylated Interferon alpha-2a does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pegylated Interferon alpha-2a in United States?
ANRS, Emerging Infectious Diseases is the originator. The local marketing authorisation holder may differ — check the official source linked above.